Ligand-based approach to in silico pharmacology: Nuclear receptor profiling

Journal of Chemical Information and Modeling

Volumn 46, Issue 6, 2006, Pages 2725-2736

  Mestres, Jordi ^a   Martín Couce, Lidia ^a   Gregori Puigjané, Elisabet ^a   Cases, Montserrat ^a   Boyer, Scott ^b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIBLIOGRAPHIC RETRIEVAL SYSTEMS; DRUG PRODUCTS; INFORMATION ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR STRUCTURE; PROTEINS;

BIOACTIVE LIGANDS; CHEMICAL LIBRARIES; NUCLEAR RECEPTORS; SILICO PHARMACOLOGY;

PHARMACOKINETICS;

CELL RECEPTOR; LIGAND;

ANIMAL; ARTICLE; CHEMICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; COMPUTER PROGRAM; CONFORMATION; DRUG DESIGN; ENTROPY; HUMAN; INSTRUMENTATION; METHODOLOGY; PHARMACEUTICS; PROTEIN BINDING; STATISTICAL MODEL;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; ENTROPY; HUMANS; LIGANDS; MODELS, CHEMICAL; MODELS, STATISTICAL; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SOFTWARE; TECHNOLOGY, PHARMACEUTICAL;

EID: 33845777604     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci600300k     Document Type: Article

References (75)

1. Schreiber, S. L. Small Molecules: The Missing Link in the Central Dogma. Nature Chem. Biol. 2005, 1, 64-66.
2. Bredel, M.; Jacoby, E. Chemogenomics: An Emerging Strategy for Rapid Target and Drug Discovery. Nature Rev. Genet. 2004, 5, 262-275.
3. Walters, W. P.; Namchuk, M. Designing Screens: How to Make your Hits a Hit. Nature Rev. Drug Discovery 2003, 2, 259-266.
4. Ramström, O.; Lehn, J.-M. Drug Discovery by Dynamic Combinatorial Libraries. Nature Rev. Drug Discovery 2002, 1, 26-36.
5. Sundberg, S. A. High-Throughput and Ultrahigh-Throughput Screening: Solution- and Cell-Based Approaches. Curr. Opin. Biotechnol. 2000, 11, 47-53.
6. Kauvar, L. M.; Higgins, D. L.; Villar, H. O.; Sportsman, J. R.; Engqvist-Goldstein, A.; Bukar, R.; Bauer, K. E.; Dilley, H.; Rocke, D. M. Predicting Ligand Binding to Proteins by Affinity Fingerprinting. Chem. Biol. 1995, 2, 107-118.
7. Weinstein, J. N.; Myers, T. G.; O'Connor, T. M.; Friend, S. H.; Fornace, A. J., Jr.; Kohn, K. W.; Fojo, T.; Bates, S. E.; Rubinstein, L. V.; Anderson, N. L.; Buolamwini, J. K.; van Osdol, W. W.; Monks, A. P.; Scudiero, D. A.; Sausville, E. A.; Zaharevitz, D. W.; Bunow, B.; Viswanadhan, V. N.; Johnson, G. S.; Wittes, R. E.; Paull, K. D. An Information-Intensive Approach to the Molecular Pharmacology of Cancer. Science 1997, 275, 343-349.
8. MacBeath, G.; Koehler, A. N.; Schreiber, S. L. Printing Small Molecules as Microarrays and Detecting Protein-Ligand Interactions en Masse. J. Am. Chem. Soc. 1999, 121, 7967-7968.
9. Poulain, R.; Horvath D.; Bonnet, B.; Eckhoff, C.; Chapelain, B.; Bodinier, M.-C.; Déprez, B. From Hit to Lead: Analyzing Structure-Profile Relationships. J. Med. Chem. 2001, 44, 3391-3401.
10. Rabow, A. A.; Shoemaker, R. H.; Sausville, E. A.; Covell, D. G. Mining the National Cancer Institute's Tumor Screening Database: Identification of Compounds with Similar Cellular Activities. J. Med. Chem. 2002, 45, 818-840.
11. Greenbaum, D. C.; Arnold, W. D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, J.; Toba, S.; Chehade, K.; Brömme, D.; Kuntz, I. D.; Bogyo, M. Small Molecule Affinity Fingerprinting: A Tool for Enzyme Family Subclassification, Target Identification, and Inhibitor Design. Chem. Biol. 2002, 9, 1085-1094.
12. Kunkel, E. J.; Dea, M.; Ebens, A.; Hytopoulos, E.; Melrose, J.; Nguyen, D.; Ota, K. S.; Plavec, I.; Wang, Y.; Watson, S. R.; Butcher, E. C.; Berg, E. L. An Integrative Biology Approach for Analysis of Drug Action in Models of Human Vascular Inflammation. FASEB J. 2004, 18, 1279-1281.
13. Giaever, G.; Flaherty, P.; Kumm, J.; Proctor, M.; Nislow, C.; Jaramillo, D. F.; Chu, A. M.; Jordan, M. L; Arkin, A. P.; Davis, R. W. Chemogenomic Profiling: Identifying the Functional Interactions of Small Molecules in Yeast. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 793-798.
14. Szakács, G.; Annereau, J.-P.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K. J.; Reinhold, W.; Guo, Y.; Kruh, G. D.; Reimers, M.; Weinstein, J. N.; Gottesman, M. M. Predicting Drug Sensitivity and Resistance: Profiling ABC Transporter Genes in Cancer Cells. Cancer Cell 2004, 6, 129-137.
15. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic Shotguns versus Magic Bullets: Selectively Non-Selective Drugs for Mood Disorders and Schizophrenia. Nature Rev. Drug Discovery 2004, 3, 353-359.
16. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors. Nature Biotechnol. 2005, 23, 329-336.
17. Fliri, A. F.; Loging, W. T.; Thadeio, P. F.; Volkmann, R. A. Analysis of Drug Induced Effect Patterns to Link Structure and Side Effects of Medicines. Nature Chem. Biol. 2005, 1, 389-397.
18. Ramanathan, A.; Wang, C.; Schreiber, S. L. Perturbational Profiling of a Cell-Line Model of Tumorigenesis by Using Metabolic Measurements. Proc. Natl. Acad. Sci. 2005, 102, 5992-5997.
19. Haiching M.; Horiuchi, K. Y. Chemical Microarray: A New Tool for Drug Screening and Discovery. Drug Discovery Today 2006, 11, 661-668.
20. Bajorath, J. Integration of Virtual and High-Throughput Screening. Nature Rev. Drug Discovery 2002, 1, 882-894.
21. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can We Rationally Design Promiscuous Drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136.
22. Krejsa, C. M.; Horvath, D.; Rogalski, S. L. Penzotti, J. E.; Mao, B.; Barbosa, F.; Migeon, J. C. Predicting ADME Properties and Side Effects: The BioPrint Approach. Curr. Opin. Drug Discovery Dev. 2003, 6, 470-480.
23. Root, D. E.; Flaherty, S. P.; Kelley, B. P.; Stockwell, B. R. Biological Mechanism Profiling Using an Annotated Compound Library. Chem. Biol. 2003, 10, 881-892.
24. Strausberg, R. L.; Schreiber, S. L. From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes. Science 2003, 300, 294-295.
25. Schuffenhauer, A.; Floersheim, P.; Acklin, P.; Jacoby, E. Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins. J. Chem. Inf. Comput. Sci. 2003, 43, 391-405.
26. Horvath, D.; Jeandenans, C. Neighborhood Behavior of In Silico Structural Spaces with Respect to In Vitro Activity Spaces: A Novel Understanding of the Molecular Similarity Principle in the Context of Multiple Receptor Binding Profiles. J. Chem. Inf. Comput. Sci. 2003, 43, 680-690.
27. Poroikov, V. V.; Filimonov, D. A.; Borodina, Y. V.; Lagunin, A. A.; Kos, A. Robustness of Biological Activity Spectra Predicting by Computer Program PASS for Noncongeneric Sets of Chemical Compounds. J. Chem. Inf. Comput. Sci. 2000, 40, 1349-1355.
28. Cleves, A. E.; Jain, A. N. Robust Ligand-Based Modeling of the Biological Targets of Known Drugs. J. Med. Chem. 2006, 49, 2921-2938.
29. Nidhi; Glick, M.; Davies, J. W.; Jenkins, J. L. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases. J. Chem. Inf. Model. 2006, 46, 1124-1133.
30. Savchuk, N. P.; Balakin, K. V.; Tkachenko, S. E. Exploring the Chemogenomic Knowledge Space with Annotated Chemical Libraries. Curr. Opin. Chem. Biol. 2004, 8, 412-417.
31. MDL Comprehensive Medicinal Chemistry (CMC-ID) Database; MDL Information Systems, Inc: San Leandro, CA. CMC is an updated electronic version of Comprehensive Medicinal Chemistry; Pergamon Press: Elmsford, NY, 1990; Vol. 6.
32. World Drug Index; Derwent Information Ltd.: London.
33. MDL Drug Data Report; MDL Information Systems. Inc.: San Leandro, CA.
34. Olah, M.; Mracec, M.; Ostopovici, L.; Rad, R.; Bora, A.; Hadaruga, N.; Olah, I.; Banda, M.; Simon, Z.; Oprea, T. I. WOMBAT: World of Molecular Bioactivity. In Chemoinformatics in Drug Discovery; Oprea, T. I., Ed.; Wiley-VCH: New York, 2004; pp 223-239; Sunset Molecular Discovery, LLC.: Santa Fe, NM, 2004.
35. Vieth, M.; Sutherland, J. J.; Robertson, D. H.; Campbell, R. M. Kinomics: Characterizing the Therapeutically Validated Kinase Space. Drug Discovery Today 2005, 10, 839-846.
36. Vieth, M.; Sutherland, J. J. Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs. J. Med. Chem. 2006, 49, 3451-3453.
37. Koch, M. A.; Waldmann, H. Protein Structure Similarity Clustering and Natural Product Structure as Guiding Principles in Drug Discovery. Drug Discovery Today 2005, 10, 471-483.
38. Klabunde, T.; Hessler, G. Drug Design Strategies for Targeting G Protein-Coupled Receptor. ChemBioChem 2002, 3, 928-944.
39. Gronemeyer, H.; Gustafsson, J. A.; Laudet, V. Principles for Modulation of the Nuclear Receptor Superfamily. Nature Rev. Drug Discovery 2004, 3, 950-964.
40. Francis, G. A.; Fayard, E.; Picard, F.; Auwerx, J. Nuclear Receptors and the Control of Metabolism. Annu. Rev. Physiol. 2003, 65, 261-311.
41. Gregori-Puigjané, E.; Mestres, J. SHED; Shannon Entropy Descriptors from Topological Feature Distributions. J. Chem. Inf. Model. 2006, 46, 1615-1622.
42. Elsevier MDL, San Leandro, CA. http://www.mdli.com/ (accessed May 2006).
43. Tripos, Inc., St. Louis, MO, http://www.tripos.com/mol2/atom_types.html (accessed May 2006).
44. Cases, M.; García-Sema, R.; Hettne, K.; Weeber, M.; van der Lei, J.; Boyer, S.; Mestres, J. Chemical and Biological Profiling of an Annotated Compound Library Directed to the Nuclear Receptor Family. Curr. Top. Med. Chem. 2005, 5, 763-772.
45. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures. J. Chem. Inf. Comput. Sci. 2004, 44, 1177-1185.
46. Sheridan, R. P.; Feuston, B. P.; Maiorov, V. N.; Kearsley, S. K. Similarity to Molecules in the Training Set is a Good Discriminator for Prediction Accuracy in QSAR. J. Chem. Inf. Comput. Sci. 2004, 44, 1912-1928.
47. Douguet, D.; Thoreau, E.; Grassy, G. Quantitative Structure-Activity Relationship Studies of RAR α, β, and γ Retinoid Agonists. Quant. Struct-Act. Relat. 1999, 18, 107-123.
48. Benbrook, D. M.; Subramanian, S.; Gale, J. B.; Liu, S.; Brown, C. W.; Boehm, M. F.; Berlin, K. D. Synthesis and Characterization of Heteroarotinoids Demonstrate Structure Specificity Relationships. J. Med. Chem. 1998, 41, 3753-3757.
49. Maloney, P. R.; Parks, D. J.; Haffner, C. D.; Fivush, A. M.; Chandra, G.; Plunket, K. D.; Creech, K. L.; Moore, L. B.; Wilson, J. G.; Lewis, M. C.; Jones, S. A.; Willson, T. M. Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR. J. Med. Chem. 2000, 43, 2971 -2974.
50. Canan Koch, S. S.; Dardashti, L. J.; Hebert, J. J.; White, S. K.; Croston, G. E.; Flatten, K. S.; Heyman, R. A.; Nadzan, A. M. Identification of the First Retinoid X Receptor Homodimer Antagonist. J. Med. Chem. 1996, 39, 3229-3234.
51. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape; A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003, 13, 2498-2504.
52. Ekins, S.; Kirillov, E.; Rakhmatulin, E. A.; Nikolskaya, T. A Novel Method for Visualizing Nuclear Hormone Receptor Networks Relevant to Drug Metabolism. Drug Metab. Dispos. 2005, 33, 474-481.
53. Kretschmer, X. C.; Baldwin, W. S. CAR and PXR: Xenosensors of Endocrine Disrupters? Chem. Biol. Interact. 2005, 155, 111-128.
54. Ding, X.; Lichti, K.; Staudinger, J. L. The Micoestrogen Zearalenone Induces CYP3A Through Activation of the Pregnane X Receptor. Toxicol. Sci. 2006, 91, 448-455.
55. Oberdorster, E.; Clay, M. A.; Cottam, D. M.; Wilmot, F. A.; McLachlan, J. A.; Milner, M. J. Common Phytochemicals are Ecdysteroid Agonists and Antagonists: A Possible Evolutionary Link Between Vertebrate and Invertebrate Steroid Hormones. J. Steroid. Biochem. Mol. Biol. 2001, 77, 229-238.
56. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.; Morelli, A.; Pruzanski, M.; Pellicciari, R. Cross-talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor y Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis. J. Pharmacol. Exp. Ther. 2005, 315, 58-68.
57. Kassam, A.; Miao, B.; Young, P. R.; Mukherjee, R. Retinoid X Receptor (RXR) Agonist-Induced Antagonism of Farnesoid X Receptor (FXR) Activity Due to Absence of Coactivator Recruitment and Decreased DNA Binding. J. Biol. Chem. 2003, 278, 10028-10032.
58. Lloyd, D. G.; Hughes, R. B.; Zisterer, D. M.; Williams, D. C.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Meegan, M. J. Benzoxepin-Derived Estrogen Receptor Modulators: A Novel Molecular Scaffold for the Estrogen Receptor. J. Med. Chem. 2004, 47, 5612-5615.
59. Fang, H.; Tong, W.; Shi, L. M.; Blair, R.; Perkins, R.; Branham, W.; Hass, B. S.; Xie, Q.; Dial, S. L.; Moland, C. L.; Sheehan, D. M. Structure-Activity Relationships for a Large Diverse Set of Natural, Synthetic, and Environmental Estrogens. Chem. Res. Toxicol. 2001, 14, 280-294.
60. Hashimoto, Y. Structural Development of Synthetic Retlnoids and Thalidomide-Related Molecules. Cancer Chemother. Pharmacol. 2003, 52, S12-S23.
61. Douguet, D.; Thoreau, E.; Grassy, G. Quantitative Structure-Activity Relationship Studies of RAR α, β, γ Retinoid Agonists. Quant. Struct.-Act. Relat. 1999, 18, 107-123.
62. Vuligonda, V.; Garst, M. E.; Chandraratna, R. A. S. Stereoselective Synthesis and Receptor Activity of Conformationally Defined Retinoid X Receptor Selective Ligands. Bioorg. Med. Chem. Lett. 1999, 9, 589-594.
63. Ohta, K.; Tsuji, M.; Kawachi, E.; Fukasawa, H.; Hashimoto, Y.; Shudo, K.; Kagechika, H. Potent Retinoid Synergists with a Diphenylamine Skeleton. Biol. Pharm. Bull. 1998, 21, 544-546.
64. Targeted Libraries Generation 1; Enamine: Kiev, Ukraine; www.enamine.net.
65. Saurat, J.-H. Retinoids and Psoriasis: Novel Issues in Retinoid Pharmacology and Implications for Psoriasis Treatment. J. Am. Acad. Dermatol. 1999, 41, S2-S6.
66. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensch, W. R.; Barr, R. J.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B. Design and Synthesis of a Potent and Selective Triazole-Based Peroxisome Proliferator-Activated Receptor a Agonist J. Med. them. 2003, 46, 5121-5124.
67. Kurtz, T. W. Treating the Metabolic Syndrome: Telmisartan as a Peroxisome Proliferator-Activated Receptor y Activator. Acta Diabetol. 2005, 42, 89-816.
68. Zhi, L.; Tegley, C. M.; Kallel, E. A.; Marschke, K. B.; Mais, D. E.; Gottardis, M. M.; Jones, T. K. 5-Aryl-1,2-Dihydrochromeno[3,4-f] Quinolines: A Novel Class of Non-Steroidal Human Progesterone Receptor Agonists. J. Med. Chem. 1998, 41, 291-302.
69. Brandes, L. J.; MacDonald, L. M.; Bogdanovic, R. P. Evidence that the Antiestrogen Binding Site is a Histamine or Histamine-like Receptor. Biochem. Biophys. Res. Comm. 1985, 126, 905-910.
70. Dhar, A.; Liu, S.; Klucik, J.; Berlin, K. D.; Madler, M. M.; Lu, S.; Ivey, R. T.; Zacheis, D.; Brown, C. W.; Nelson, E. C.; Birckbichler, P. J.; Benbrook, D. M. Synthesis, Structure-Activity Relationships, and RAR γ-Ligand Interactions of Nitrogen Heteroarotinoids. J. Med. Chem. 1999, 42, 3602-3614.
71. Chandraratna, R. A. Tazarotene: First of a New Generation of Receptor-Selective Retinoids. Br. J. Dermatol. 1996, 135, 18-25.
72. Hashimoto, Y.; Miyachi, H. Nuclear Receptor Antagonists Designed Based on the Helix-Folding Inhibition Hypothesis. Bioorg. Med. Chem. 2005, 13, 5080-5093.
73. Ahmadiani, A.; Mandgary, A.; Sayyah, M. Anticonvulsant Effect of Flutamide on Seizures Induced by Pentylenetetrazole: Involvement of Benzodiazepine Receptors. Epilepsia 2003, 44, 629-635.
74. Zhang, Q.; Muegge, I. Scaffold Hopping Through Virtual Screening Using 2D and 3D Similarity Descriptors: Ranking, Voting, and Consensus Scoring. J. Med. Chem. 2006, 49, 1536-1548.
75. Mestres J. Representativity of Target Families in the Protein Data Bank: Impact for Family-Directed Structure-Based Drug Discovery. Drug Discovery Today 2005, 10, 1629-1637.